Status:
COMPLETED
Positron Emission Tomography Scanning and Epstein-Barr Virus DNA Levels in the Staging and Follow-up of Nasopharyngeal Carcinoma.
Lead Sponsor:
University Health Network, Toronto
Conditions:
Nasopharyngeal Carcinoma
Eligibility:
All Genders
Brief Summary
The standard treatment for nasopharyngeal cancer involves either radiation alone or radiation plus chemotherapy. Before the start of treatment,patients require an imaging scan to assess the extent of ...
Detailed Description
1. Patients with nasopharyngeal carcinoma are staged according to the 2002 American Joint Committee on Cancer (AJCC) criteria. MRI is the imaging modality of choice for staging and follow-up of nasoph...
Eligibility Criteria
Inclusion
- \- 1. Patients with histologically diagnosed nasopharyngeal carcinoma presenting to the University Health Network for which a course of curative radiation therapy +/- chemotherapy is planned.
- 2\. Patient is able to provide informed consent and is willing to adhere to the study protocol.
Exclusion
- \- 1. Patients with metastatic disease. 2. Lactating or pregnant females. 3. Medical or psychological conditions such as claustrophobia, etc., that in the opinion of the referring MD or study investigator, would make the patient unable to tolerate the study procedures.
- 4\. Presence of a second malignancy or a history of another malignancy active within the last 5 years, with the exception of non-head and neck, non-melanomatous cutaneous malignancy.
Key Trial Info
Start Date :
March 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2017
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00188253
Start Date
March 1 2005
End Date
February 1 2017
Last Update
October 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Hospital, University Health Network
Toronto, Ontario, Canada, M5G 2M9